Andrea Rizzi

This inventor holds 22 USPTO granted patents and 12 published patent applications, plus 3 CIPO patents and 19 EPO patents, primarily in Pharmaceutical Chemistry. Top assignee: Chiesi Farmaceutici S.p.a.. Active years: 2009-2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Andrea Rizzi. Retrieved from https://idiyas.com/inventor/andrea-rizzi

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank

USPTO Granted Patents = 22 (Patent Applications = 12)

% Patents Active = 50.0

CIPO Patents = 3 (Patent Applications = 15)

EPO Patents = 19 (Patent Applications = 27)

Average Co-Inventor Count = 5.0

ph-index = 4

Forward Citations = 52(Granted Patents)

Company Filing History:

22 out of 343

Chiesi Farmaceutici S.p.a.

patents

Years Active: 2009-2026

Loading Chart...

Areas of Expertise:

Pyrrolidine Derivatives

Tetrahydrothieno Pyridine

LPA Receptor Inhibitors

Muscarinic Receptor Antagonist

PDE-4 Inhibitors

Neurodegenerative Diseases

Quinuclidine Derivatives

Pharmaceutical Compositions

Chronic Obstructive Pulmonary Disease

Beta2 Adrenergic Receptor Agonist

1-Phenylalkanecarboxylic Acid

22 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12760004 - Pyrrolidine derivatives as DDRs inhibitors (2026-10-13),

2. 12723052 - Tetrahydrothieno pyridine derivatives as DDRs inhibitors (2026-09-01),

3. 12617801 - Tetrahydrothieno pyridine derivatives as DDRS inhibitors (2026-05-05),

4. 12454530 - Amido cyclohexane acid derivatives as LPA receptor inhibitors (2025-10-28),

5. 10280193 - Isoxazolidine derivatives (2019-05-07),

6. 10196386 - Compounds having muscarinic receptor antagonist and beta2 adrenergic receptor agonist activity (2019-02-05),

7. 10087176 - 3,5-dichloro,4-(3,4-(cyclo-)alkoxyphenyl)--2-carbonyloxy)ethyl)pyridine derivatives as PDE-4 inhibitors (2018-10-02),

8. 10004728 - Compounds having muscarinic receptor antagonist and BETA2 adrenergic receptor agonist activity (2018-06-26),

9. 9932338 - Compounds having muscarinic receptor antagonist and BETA2 adrenergic receptor agonist activity (2018-04-03),

10. 9845337 - Isoxazolidine derivatives (2017-12-19),

11. 9662323 - Compounds having muscarinic receptor antagonist and beta2 adrenergic receptor agonist activity (2017-05-30),

12. 9579314 - Compounds having muscarinic receptor antagonist and BETA2 adrenergic receptor agonist activity (2017-02-28),

13. 9199980 - Compounds (2015-12-01),

14. 9012644 - Compounds having muscarinic receptor antagonist and beta2 adrenergic receptor agonist activity (2015-04-21),

15. 8877774 - Compounds having muscarinic receptor antagonist and beta2 Adrenergic receptor agonist activity (2014-11-04),

Sure, here is the article about inventor Andrea Rizzi:

Title: Innovator Spotlight: Andrea Rizzi - Revolutionizing Pharmaceutical Treatments

Introduction:

Andrea Rizzi, a brilliant inventor hailing from Parma, Italy, has made significant contributions to the field of pharmaceuticals with her innovative patents. With a total of 18 patents to her name, Andrea Rizzi has been at the forefront of developing groundbreaking solutions for respiratory and inflammatory diseases.

Latest Patents:

1. Isoxazolidine derivatives - Anti-inflammatory and antiallergic compounds of the glucocorticosteroid series: Andrea Rizzi's patent focuses on compounds that are instrumental in treating respiratory diseases characterized by airway obstruction.

2. Compounds having muscarinic receptor antagonist and beta2 adrenergic receptor agonist activity: Her patent highlights compounds that act as both muscarinic receptor antagonists and beta2 adrenergic receptor agonists, essential for the prevention and treatment of broncho-obstructive or inflammatory diseases.

Career Highlights:

Andrea Rizzi is a valued member of Chiesi Farmaceutici S.p.A., a renowned pharmaceutical company. Her dedication and expertise have played a pivotal role in driving innovation within the company and the pharmaceutical industry as a whole.

Collaborations:

In her pursuit of excellence, Andrea Rizzi has collaborated closely with esteemed colleagues such as Fabio Rancati and Ian Linney. Together, they have worked tirelessly to bring revolutionary pharmaceutical treatments to the market, improving the lives of countless individuals worldwide.

Conclusion:

Andrea Rizzi's relentless pursuit of innovation and her remarkable contributions to the pharmaceutical domain underscore her status as a pioneering inventor. Her patents have not only advanced medical treatments but have also set a new benchmark for research in the field. Andrea Rizzi's work serves as an inspiration to aspiring inventors and underscores the transformative power of innovation in healthcare.

If you have any more specific requests or need further information, feel free to ask!

Profile summary based on public USPTO records.